MJR-35 phase 3 study to investigate the efficacy and safety in patients with adenomyosis (a multicenter, randomized, double-blind, placebo-controlled, parallel-group study)

Trial Profile

MJR-35 phase 3 study to investigate the efficacy and safety in patients with adenomyosis (a multicenter, randomized, double-blind, placebo-controlled, parallel-group study)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Dienogest (Primary)
  • Indications Adenomyosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mochida Pharmaceutical
  • Most Recent Events

    • 24 Nov 2015 Status changed from not yet recruiting to completed.
    • 03 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top